Pfizer strikes an R&D partnership with Flagship’s ProFound as it looks for next-gen obesity assets

Pfiz­er is open­ing up an­oth­er road to the obe­si­ty mar­ket, an­nounc­ing a part­ner­ship with one of Flag­ship Pi­o­neer­ing’s star­tups to iden­ti­fy new mol­e­cules and tar­gets …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.